Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 14, 2024 (filed on Mar 14, 2024)Insider Name:Green Kevin DennisOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-21,497Price:$1.97
-
Mar 14, 2024 (filed on Mar 14, 2024)Insider Name:Jensen ChrystalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-17,824Price:$1.97
-
Mar 14, 2024 (filed on Mar 14, 2024)Insider Name:Jayaraman Vivek KOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-26,794Price:$1.97
-
Mar 14, 2024 (filed on Mar 14, 2024)Insider Name:Greenman William MarinerOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-63,611Price:$2.02
-
Mar 14, 2024 (filed on Mar 14, 2024)Insider Name:Corash Laurence MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-14,360Price:$1.97
-
Mar 14, 2024 (filed on Mar 14, 2024)Insider Name:Benjamin Richard JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-17,738Price:$1.97
-
Mar 13, 2024 (filed on Mar 14, 2024)Insider Name:Green Kevin DennisOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-21,058Price:$2.02
-
Mar 13, 2024 (filed on Mar 14, 2024)Insider Name:Moore CarolOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-10,416Price:$1.97
-
Mar 13, 2024 (filed on Mar 14, 2024)Insider Name:Moore CarolOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-10,203Price:$2.06
-
Mar 13, 2024 (filed on Mar 14, 2024)Insider Name:Jensen ChrystalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-17,460Price:$2.06
Filings by filing date
-
Mar 12, 2024 (filed on Mar 14, 2024)Insider Name:Green Kevin DennisOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-21,666Price:--
-
Mar 14, 2024 (filed on Mar 14, 2024)Insider Name:Green Kevin DennisOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-21,497Price:$1.97
-
Mar 13, 2024 (filed on Mar 14, 2024)Insider Name:Green Kevin DennisOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-21,058Price:$2.02
-
Mar 12, 2024 (filed on Mar 14, 2024)Insider Name:Green Kevin DennisOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:21,666Price:--
-
Mar 12, 2024 (filed on Mar 14, 2024)Insider Name:Moore CarolOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-11,666Price:--
-
Mar 13, 2024 (filed on Mar 14, 2024)Insider Name:Moore CarolOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-10,416Price:$1.97
-
Mar 13, 2024 (filed on Mar 14, 2024)Insider Name:Moore CarolOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-10,203Price:$2.06
-
Mar 12, 2024 (filed on Mar 14, 2024)Insider Name:Moore CarolOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:11,666Price:--
-
Mar 12, 2024 (filed on Mar 14, 2024)Insider Name:Jensen ChrystalOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-16,666Price:--
-
Mar 14, 2024 (filed on Mar 14, 2024)Insider Name:Jensen ChrystalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-17,824Price:$1.97
News
Biz Brief
Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2550 STANWELL DRIVE CONCORD CA 94520 |
Tel: | N/A |
Website: | https://www.cerus.com |
IR: | See website |
Key People | ||
William M. Greenman President, Chief Executive Officer, Director | Kevin Dennis Green Chief Financial Officer, Vice President - Finance | Vivek K. Jayaraman Chief Operating Officer |
Alicia Goodman Chief Human Resource Officer | Carol M. Moore Senior Vice President - Regulatory Affairs, Quality and Clinical | Laurence M. Corash Chief Scientific Officer |
Chrystal N. Menard Chief Legal Officer, General Counsel | Richard J. Benjamin Chief Medical Officer |
Business Overview |
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced. |
Financial Overview |
For the fiscal year ended 31 December 2023, Cerus Corp revenues decreased 1% to $186.8M. Net loss decreased 12% to $37.5M. Revenues reflect United States segment decrease of 3% to $123.7M, France segment decrease of 4% to $18.5M. Lower net loss reflects Stock-based Compensation in SGA decrease of 23% to $14.4M (expense), Other income, net increase from $1.7M (expense) to $1.8M (income). |
Employees: | 288 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $356.57M as of Dec 31, 2023 |
Annual revenue (TTM): | $186.80M as of Dec 31, 2023 |
EBITDA (TTM): | -$23.73M as of Dec 31, 2023 |
Net annual income (TTM): | -$37.49M as of Dec 31, 2023 |
Free cash flow (TTM): | -$47.77M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $13.94M as of Dec 31, 2023 |
Shares outstanding: | 181,282,725 as of Feb 8, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |